Inflammatory or neuropathic pain in both men and women patients is treated by administering, sequentially or simultaneously, (a) nalbuphine and (b) an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt or prodrug of nalbuphine and/or the opioid antagonist. Preferably, administration is made of (a) an amount of from about 3 to about 8 mg nalbuphine and (b) from about 0.2 to about 0.8 mg of an opioid antagonist selected from naloxone, naltrexone and nalmefene, or a salt and/or prodrug of either (in an amount that produces in a patient the same blood concentration of the compound in question as would administration of said amount of the nalbuphine or opioid antagonist itself). Treatment of both inflammatory and neuropathic pain can be achieved; side effects common with .mu.-opioids such as morphine were not observed.

Воспалительная или neuropathic боль в обоих людях и пациентах женщин обработана путем administering, последовательн или одновременно, (a) nalbuphine и (b) антагонист opioid выбрали от naloxone, naltrexone и nalmefene, или соли или prodrug nalbuphine and/or антагониста opioid. Предпочтительн, делают администрацию (a) количество от около 3 к nalbuphine магния около 8 и (b) от около 0.2 до около 0.8 магния антагониста opioid выбранного от naloxone, naltrexone и nalmefene, или соли and/or prodrug того (в количестве которое производит в пациенте такая же концентрация крови смеси в вопросе как администрация сама сказанного количества антагониста nalbuphine или opioid). Обработки и воспалительной и neuropathic боли можно достигнуть; не наблюдались побочные эффекты общие с mu.-opioids such as морфин.